ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
6,086.37
0.61%
US Tech 100
21,138.80
-0.57%
다우존스 지수
44,156.73
0.30%
Bitcoin
102,245.83
-1.34%
Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. ImmunoPrecise Antibodies Ltd (IPA)

  7. ImmunoPrecise Antibodies Ltd (IPA) 뉴스

IPA

ImmunoPrecise Antibodies (IPA)

ImmunoPrecise Antibodies Ltd
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:IPA
일자시간출처헤드라인심볼기업
2025/01/2304:19Business WireIPA (ImmunoPrecise Antibodies), pionnier des thérapies GLP-1 conçues par l'IA : Un nouveau chapitre potentiel en matière de traitement du diabèteNASDAQ:IPAImmunoPrecise Antibodies Ltd
2025/01/2300:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
2025/01/2221:02Business WireIPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes TreatmentNASDAQ:IPAImmunoPrecise Antibodies Ltd
2025/01/1811:25Business WireImmunoPrecise Antibodies redéfinit sa stratégie de pipeline en faisant appel à l'IA et à l'innovation basée sur les principes premiers pour la découverte de médicamentsNASDAQ:IPAImmunoPrecise Antibodies Ltd
2025/01/1801:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
2025/01/1722:01Business WireImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles InnovationNASDAQ:IPAImmunoPrecise Antibodies Ltd
2025/01/0400:20Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
2025/01/0121:44Business WireL'IPA annonce la démission de sa directrice financièreNASDAQ:IPAImmunoPrecise Antibodies Ltd
2025/01/0109:56Business WireIPA Announces Resignation of Chief Financial OfficerNASDAQ:IPAImmunoPrecise Antibodies Ltd
2024/12/2402:02Business WireImmunoPrecise Antibodies (IPA) démontre une solide confiance du marché avec des achats d'actions par des membres de la directionNASDAQ:IPAImmunoPrecise Antibodies Ltd
2024/12/2323:03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
2024/12/2322:30Business WireImmunoPrecise Antibodies (IPA) Demonstrates Strong Market Confidence with Insider Share PurchasesNASDAQ:IPAImmunoPrecise Antibodies Ltd
2024/12/2002:56Business WirePrésentation de l'IPA à la Microcap Conference 2025NASDAQ:IPAImmunoPrecise Antibodies Ltd
2024/12/1922:00Business WireIPA to Present at The Microcap Conference 2025NASDAQ:IPAImmunoPrecise Antibodies Ltd
2024/12/1120:34Business WireImmunoPrecise Antibodies (IPA) publie ses résultats financiers et les faits saillants de ses activités du deuxième trimestre de l’exercice 2025NASDAQ:IPAImmunoPrecise Antibodies Ltd
2024/12/1022:37Edgar (US Regulatory)Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]NASDAQ:IPAImmunoPrecise Antibodies Ltd
2024/12/1022:36Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
2024/12/1022:33Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
2024/12/1022:30Business WireImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025NASDAQ:IPAImmunoPrecise Antibodies Ltd
2024/12/0520:23Business WireL'IPA participera à la prochaine conférence de découverte en tête-à-tête d'investisseurs organisée par The Benchmark CompanyNASDAQ:IPAImmunoPrecise Antibodies Ltd
2024/12/0422:00Business WireIPA to Present at The Benchmark Company’s Upcoming Discovery One-on-One Investor ConferenceNASDAQ:IPAImmunoPrecise Antibodies Ltd
2024/12/0413:08Business WireL'IPA publiera ses résultats financiers et les faits importants de son activité récente pour le deuxième trimestre de l'exercice 2025 le 10 décembre 2024NASDAQ:IPAImmunoPrecise Antibodies Ltd
2024/12/0322:33Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
2024/12/0322:30Business WireIPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025 on December 10, 2024NASDAQ:IPAImmunoPrecise Antibodies Ltd
2024/11/1505:13Business WireUne percée commerciale de 20 milliards de dollars : l'IPA est pionnière dans le développement d'anticorps à fort impact pour les thérapies anticancéreuses ADC de nouvelle générationNASDAQ:IPAImmunoPrecise Antibodies Ltd
2024/11/1323:17Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
2024/11/1323:00Business Wire$20 Billion Market Breakthrough: IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer TherapiesNASDAQ:IPAImmunoPrecise Antibodies Ltd
2024/11/0515:53Business WireImmunoPrecise annonce son TECHDAY, un événement dédié à l'innovation de pointe en matière d'IA et de produits biologiquesNASDAQ:IPAImmunoPrecise Antibodies Ltd
2024/11/0422:54Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
2024/11/0422:01Business WireImmunoPrecise to Host TECHDAY: Cutting-Edge AI and Biologics InnovationNASDAQ:IPAImmunoPrecise Antibodies Ltd
 검색 관련기사 보기:NASDAQ:IPA

최근 히스토리

NASDAQ
NVDA
NVIDIA
USOTC
BNPQY
BNP Paribas (QX)
NASDAQ
AMZN
Amazon.com
FX
USDJPY
US Dollar vs Yen
NASDAQ
GOOGL
Alphabet
COIN
AVAXUSD
Avalanche
NASDAQ
AAPL
Apple
FX
USDEUR
US Dollar vs Euro
NYSE
KO
Coca Cola
COIN
DOGEUSD
Dogecoin
NYSE
MCD
McDonalds
SPI
SP500
S&P 500
COIN
SOLUSD
Solana
NYSE
MRK
Merck
USI
USTECH100
US Tech 100
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유